Skip to main content

INVESTIGACION TRASLACIONAL PERSONALIZADA EN ENFERMEDADES RARAS CON IMPLICACIONES VASCULARES: DIAGNOSTICO, MODELOS PATOLOGICOS Y ENSAYOS DE TERAPIAS DE REPOSICIONAMIENTO

PID2023-146593OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2023
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting aggressive VHL disease with a germinal mutation in the CHEK2 gene: A personalized approach

  • Albiñana, Virginia
  • Sarro Miguel, Clara
  • Lorente-Herraiz, Laura
  • Recio-Poveda, Lucía
  • Cuesta, Ángel M.
  • Viñas-López, Jesús
  • Aguirre, Daniel T.
  • Ruiz-Llorente, Lidia
  • Botella, Luisa María
13 p.-5 fig.-1 tab., Background: Von Hippel-Lindau (VHL) is a rare inherited dominant disorder leading to central nervous system hemangioblastomas, clear cell renal carcinoma, pheochromocytoma, and pan-creatic tumors. It affects 1 in 36,000 births, VHL patients are heterozygous for a pathogenic VHL mutation in germline. A second mutation in the other allele is required for tumor development, resulting in loss of pVHL function, responsible for degradation of Hypoxia-Inducible Factor (HIF) under normoxia. Without pVHL, HIF translocates into nucleus, inducing targets of the hypoxia program, among them genes involved in proliferation and angiogenesis. VHL disease shows variable phenotypic manifestations and different severity. A previous study analyzed a severe case of VHL with an unusually early onset and aggressive progression, carrying a heterozygous Check2 mutation., Methods: Cell cultures from three surgeries of this patient were analyzed, revealing complete loss of pVHL and multiple somatic mutations in different tumor cells. Using the “Pandrugs” algorithm as a predictive tool and inputting VHL and CHEK2 as the mutated genes, Olaparib was identified as the most suitable therapeutic option. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor., Results: In vitro, olaparib reduced cell viability by 50%, moreover combined with ICI-118,551, a beta-adrenergic receptor blocker, viability was re-duced by 80%, showing an additive effect. Conclusions: These findings highlight the role of personalized medicine showing how tailored treatments can improve clinical outcomes., This research was funded by MICINN (Ministry of Science and Innovation of Spain), grant AEI/10.13039/501100011033 number PID2020-115371RB-I00 by FEDER and MICINN grant AEI number PID2023-146593OB-I00., Peer reviewed